BioPharmSignal logoBioPharmSignal

Biotech News

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Structure Therapeutics (GPCR)Structure TherapeuticsCompany update

SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the appointment of Matthew Lang, J.D.

Open original release

Related news

GPCRStructure Therapeutics2026-05-07 20:06 EST

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

GPCRStructure Therapeutics2026-04-27 20:05 EST

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

KYMRKymera2026-07-27 20:01 EST

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

ANABAnaptysBio, Inc.2026-05-11 13:15 EST

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

ARGXArgenx2026-05-06 20:01 EST

argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer

KYMRKymera2026-07-07 11:00 EST

Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader

AVTXAvalo Therapeutics2026-06-23 11:00 EST

Avalo Therapeutics Appoints Ron Philip to Board of Directors

AVTXAvalo Therapeutics2026-06-26 11:00 EST

Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

NRIXNurix Therapeutics2026-05-14 20:06 EST

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

NRIXNurix Therapeutics2026-03-23 20:05 EST

Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting

View all latest news

Structure Therapeutics

Structure Therapeutics is a GPCR-focused company developing oral small-molecule therapies for metabolic and inflammatory diseases. Its platform aims to combine validated biology with convenient dosing.

Recent company news

GPCRStructure Therapeutics2026-05-26 20:05 EST

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

GPCRStructure Therapeutics2026-05-07 20:06 EST

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

GPCRStructure Therapeutics2026-04-27 20:05 EST

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

GPCRStructure Therapeutics2026-04-14 20:05 EST

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

GPCRStructure Therapeutics2026-03-16 11:00 EST

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Stock data

Close
48.69 USD
Market cap
2.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States